Second Quarter 2026 Financial Results

August 6, 2026

Forward-Looking Statements

This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations of Total Revenues, Non-GAAP Diluted EPS, Non-GAAP Operating Margin, gross leverage, operating cash flow and revenue compound annual growth rate (CAGR) for, in certain instances, the full-year 2026, fourth quarter and second half of 2026, and future periods, and the underlying drivers of those results, such as the expected demand and continued growth of BioMarin's Metabolic Conditions portfolio, including PALYNZIQ, and VOXZOGO, and the expected impact of the acquisition of Amicus Therapeutics, Inc. (Amicus); the anticipated benefits of the acquisition of Amicus, including the expected amount and timing of cost synergies as well as expected revenue from the addition of GALAFOLD and POMBILITI + OPFOLDA, including BioMarin's plans and expectations to accelerate growth through mid-2030s; BioMarin's plans for investment in innovation and future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of BioMarin's product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of BioMarin's commercial products and product candidates, including with respect to the potential new indication for VOXZOGO in hypochondroplasia; and potential growth opportunities and trends, including the assumptions and expectations regarding total addressable patient population (TAPP) with respect to the conditions targeted by BioMarin's product candidates and commercial products. These risks and uncertainties include, among others, those factors detailed in BioMarin's press release issued on August 6, 2026, and BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

Non-GAAP Financial Measures

This presentation includes both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income (Loss) excluding amortization, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP Research and Development (R&D) expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. Non-GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company's equity plans or convertible debt in periods when they are dilutive under Non-GAAP. Projected Gross Leverage is defined by the company as undiscounted debt (total debt excluding unamortized discount and deferred offering costs) as of the balance sheet date divided by 4 quarter projected Non-GAAP Adjusted EBITDA. Non-GAAP Adjusted EBITDA is defined by the company as GAAP Income (or Loss) from Operations excluding the impact of depreciation, amortization and stock-based compensation expense. Non-GAAP synergies is defined by the company as Amicus' legacy labor and external spend cost reductions, excluding the impact of stock-based compensation. BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because such Non-GAAP metrics are important internal measurements for BioMarin, BioMarin believes that providing this information in conjunction with GAAP information enhances investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's principal business. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its Non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this presentation may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors. With respect to historical Non-GAAP adjusted financial information, see the appendix beginning on slide 22 for the reconciliations to the comparable information reported under U.S. GAAP.

Q2’26 Financial Results Agenda:

1. Q2’26 Results and Amicus Integration Update
2. Commercial Update
3. Research & Development Update
4. Financial Results
5. Q&A

Alexander Hardy
Chief Executive Officer

Cristin Hubbard
Chief Commercial Officer

Greg Friberg
Chief R&D Officer

Brian Mueller
Chief Financial Officer

Q2’26 Key Business and Amicus Integration Updates

Alexander Hardy
Chief Executive Officer

Q2: Strengthened Rare Disease Leadership → Accelerated Growth

STRONG Q2'26 EXECUTION

$990M ▲ 20%Y/Y

Total Revenue Growth

- 25% Y/Y growth across Metabolic Conditions (formerly Enzyme Therapies), including GALAFOLD and POMBILITI + OPFOLDA
- 14% Y/Y growth of VOXZOGO; > 20% Y/Y increase in number of children treated; strong U.S. and global demand led to increased full-year guidance of at least $1 billion
- FY'26 Non-GAAP Diluted EPS guidance increased; Total Revenues midpoint raised
- Q4 expected to be highest revenue quarter in 2026

AMICUS VALUE CREATION

~$1.4B
GALAFOLD
Peak Revenue

~$1.2B
POMBILITI + OPFOLDA
Peak Revenue

- Rapid, value-creating integration of Amicus, following April 27 close
- Leverages BioMarin's global scale and capabilities platform to drive growth
- Significant cost synergies[1,2] expected to be fully realized in 2028
- Increasing operating cash flow expected; substantial EPS accretion anticipated beginning in 2027
- Accelerated de-leveraging, now targeting < 2.5x gross leverage[1] by mid-year 2027

PIPELINE MOMENTUM

Phase 3 Win

Hypochondroplasia (HCH) Potential to Expand VOXZOGO Market

- sNDA submitted for the approval of VOXZOGO for HCH based on strong pivotal data
- 5-year leadership in achondroplasia (ACH) facilitates potential launch of first targeted therapy for HCH
- BMN 820 (formerly DMX-200) Phase 3 ongoing; first-in-class oral CCR2 for FSGS; pivotal data expected 2028
- U.S. and EU approval in adolescents broadens PALYNZIQ opportunity
- Plans to fortify earlier-stage pipeline in next 12 to 18 months

Forward-looking figures are company estimates based on current portfolio; Estimated peak revenue for GALAFOLD expected by the mid-2030s and for POMBILITI + OPFOLDA by the mid-to-late-2030s; [1]Refer to slide 2 for more detail on Non-GAAP financial measures; [2]Represents approximately $280 million of cost reductions on a GAAP basis, and approximately $220 million of cost reductions on a Non-GAAP basis, expected to be fully realized in 2028, representing an approximately 50% reduction from Amicus-reported 2025 GAAP and Non-GAAP operating expenses, respectively.

Accelerating BioMarin's Growth Trajectory through Mid-2030s

- Significant Cost Synergies Expected to be Fully Realized in 2028
- GALAFOLD and POMBILITI + OPFOLDA Peak Revenue
- Expanding Combined Portfolio Non-GAAP Operating Margin
- Generating Significant Operating Cash Flow

Accelerating the GALAFOLD Peak Revenue Outlook

Galafold® (migalastat) 123 mg capsule

~10% CAGR ('27-'32)



Growth and Acceleration Levers

Driving Diagnosis and Treatment

- Globally, scale AI-enabled patient finding, genetic testing, newborn screening, and family cascade screening
- Goal to **more than double number** of U.S. patients treated with GALAFOLD (~40% of 2025 revenue from U.S.)

Driving Penetration and Global Expansion

- Goal to treat additional patients in established markets
- Expand or enter **more than 10** priority markets where BioMarin has established commercial capabilities

Accelerating the POMBILITI + OPFOLDA Peak Revenue Outlook

Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) 65 mg capsules

≥ 20% CAGR ('27-'32)



Growth and Acceleration Levers

Driving Switch and Global Expansion

- HCP and patient education; real-world-evidence generation to demonstrate the benefit of switching
- Leverage AI patient finding model that identifies patients waning on current therapy
- Increase number of U.S. treated patients by **> 7x**
- Goal to establish **more than 20 new markets** over time

Driving Diagnosis and Treatment

- Leverage BioMarin's diagnostic capabilities to identify naïve-to-treatment patients within global footprint

~$220M in Amicus Cost Synergies[1,2] Expected to Result in ~50% Reduction from Amicus-reported 2025 Non-GAAP Operating Expenses[1]

Cost Synergies Split



Key Synergies Drivers

- Significant reductions in R&D and G&A
- S&M retained; maintaining HCP and patient-facing capabilities to drive commercial expansion
- Expected to realize full cost reduction annual run rate of **~$220M in 2028**
- ~$220M represents **~50%** reduction from Amicus-reported 2025 Non-GAAP Operating Expenses of $432M

[1]Refer to slide 2 for more detail on Non-GAAP financial measures; [2]Represents approximately $280 million of cost reductions on a GAAP basis, and approximately $220 million of cost reductions on a Non-GAAP basis, expected to be fully realized in 2028, representing an approximately 50% reduction from Amicus-reported 2025 GAAP and Non-GAAP operating expenses, respectively.

Creating Significant Value Near-term and Beyond

2027

Cost Synergies[1,2] Ramping

Gross Leverage[1]

< 2.5x

(mid-year 2027)

2028

Cost Synergies Fully Realized

~$220M[2]

Annual run-rate cost reduction

~50%

Reduction from Amicus-reported 2025 Non-GAAP Operating Expenses[1] of $432M

Beyond 2030

Peak Revenue Outlook

GALAFOLD

$1.4B

by mid-2030s (~10% CAGR '27-'32)

POMBILITI + OPFOLDA

$1.2B

by mid-to-late-2030s (≥ 20% CAGR '27-'32)

GALAFOLD and POMBILITI + OPFOLDA Combined Non-GAAP Operating Margin[1]

> 60%

Substantial Non-GAAP Diluted EPS[1] Accretion Expected Beginning in 2027

Significant Increase in Operating Cash Flow Anticipated

All figures are company estimates based on current portfolio. All figures represent additive contribution from Amicus acquisition, except Gross Leverage, which is estimated for combined company; [1]Refer to slide 2 for more detail on Non-GAAP financial measures; [2]Represents approximately $280 million of cost reductions on a GAAP basis, and approximately $220 million of cost reductions on a Non-GAAP basis, expected to be fully realized in 2028, representing an approximately 50% reduction from Amicus-reported 2025 GAAP and Non-GAAP operating expenses, respectively.

Commercial Update

Cristin Hubbard
Chief Commercial Officer

Acceleration of Galafold and Pombiliti + Opfolda Underway

Galafold® (migalastat) Revenue

$ in millions



Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65 mg capsules Revenue

$ in millions



Charts are not to scale and illustrative only; Percentages reflect year-over-year change; [1]Q2'26 revenue growth calculated from unaudited pro-forma figures and includes revenue from April 1, 2026 to April 26, 2026, prior to the acquisition of Amicus

Metabolic Conditions (Formerly Enzyme Therapies): More Diversified Portfolio Drove Strong Q2'26

Metabolic Conditions Q2'26 Revenue

$ in millions



Q2'26 Dynamics

- **25%** Y/Y revenue growth, inclusive of GALAFOLD and POMBILITI + OPFOLDA
- Patients on therapy grew across all BioMarin-marketed Metabolic Conditions, both Y/Y and sequentially
- PALYNZIQ revenue grew **27%** Y/Y, driven by continued patient demand, including from ages 12+, and favorable order timing in the U.S.
- European Commission approved PALYNZIQ for adolescents 12 years and older with PKU
- Order timing in Q1 impacted VIMIZIM; full-year guidance remains the best indicator of underlying performance

Skeletal Conditions: Strong Demand in Q2'26 for VOXZOGO for ACH

VOXZOGO® Revenue

$ in millions



Percentages reflect year-over-year change

Q2'26 Dynamics

- Double-digit U.S. and OUS revenue growth and strong 2H outlook led to increased FY'26 VOXZOGO guidance
- Approximately three-quarters of VOXZOGO revenue generated OUS
- Children treated increased > 20% Y/Y globally
- > 50% of new U.S. patient starts were in < 2 y/o age group; expect continued leadership in incident market
- Revenue expected to increase in 2H vs. 1H

Pipeline Highlights

- sNDA submitted to FDA for the treatment of hypochondroplasia
- In July, FDA accepted sNDA for full approval in achondroplasia

Research & Development Update

Greg Friberg
Chief R&D Officer

2026 R&D Highlights: Recent Updates and Anticipated Milestones

Recent Updates

Completed in April – July 2026

- **VOXZOGO** Phase 3 topline data for hypochondroplasia; sNDA submitted
- **VOXZOGO** 3-year extension data (investigator sponsored study) at ENDO demonstrate sustained growth in children with hypochondroplasia
- **VOXZOGO** sNDA for full approval in achondroplasia accepted by FDA (PDUFA date: Feb. 28, 2027)
- **BMN 333** Phase 1 PK & PD data presented at ENDO
- **PALYNZIQ** EU approval received for adolescents 12 years and older with phenylketonuria

Program Status and Upcoming Milestones

Candidate	Condition	Key Highlights
VOXZOGO (vosoritide) for injection	Hypochondroplasia	• sNDA submitted; subject to FDA review and acceptance • Phase 3 full data at ESPE in September (late-breaking oral presentation) • Potential first-in-class launch in 2027
VOXZOGO (vosoritide) for injection	Idiopathic Short Stature	• Phase 2 study progressing
VOXZOGO (vosoritide) for injection	Noonan Syndrome	• Phase 2 study progressing
BMN 333	Achondroplasia	• Phase 2/3 registration-enabling study enrolling
BMN 351	Duchenne muscular dystrophy	• Phase 1/2 enrollment completed • Program update expected by year-end
BMN 820 *(formerly DMX-200)*	Focal Segmental Glomerulosclerosis	• Phase 3 study advancing

Includes both completed / ongoing and anticipated R&D highlights (non-exhaustive)

Potential Upside with BMN 820 for Focal Segmental Glomerulosclerosis (FSGS); Phase 3 Endpoint Agreed with FDA

FSGS Background and BMN 820 Opportunity

BMN 820 Total Addressable Patient Population[1] in the United States: ~30,000

FSGS Background

- FSGS is a progressive kidney disease in which scarring of the kidney's filtering units causes protein in the urine and declining kidney function over time
- Only one therapy is approved today, with a narrow label that excludes FSGS patients with nephrotic syndrome
- Durable stabilization of kidney function and complete remission, consistent with international KDIGO[2] treatment guidelines, remain significant unmet need

BMN 820 Opportunity

- First-in-class oral CCR2 inhibitor with potential to treat a broad FSGS population, including primary, genetic, and undetermined FSGS, regardless of nephrotic syndrome status
- Favorable safety and tolerability profile to date
- Studied in combination with background ARB therapy, a standard of care in FSGS
- FDA has agreed that proteinuria is an appropriate endpoint for full approval for BMN 820 in ACTION3 (Phase 3 trial)
- Phase 3 data expected in 2028

[1]Total addressable patient population (TAPP) defined as diagnosed FSGS patients ages 12 to 80 of primary, genetic, or undetermined cause, regardless of therapy status; [2]Kidney Disease: Improving Global Outcomes

Q2’26 Financial Results

Brian Mueller
Chief Financial Officer

Q2 Financial Highlights

Q2 2026 Results

In millions, except percentages and per share amounts	Q2'26	Y/Y Change
Total Revenues	$990	+20%
GAAP R&D	$207	+28%
GAAP SG&A	$396	+70%
GAAP Operating Margin	11.2%	(22.3) ppts
Non-GAAP R&D[1]	$191	+30%
Non-GAAP SG&A[1]	$253	+25%
Non-GAAP Operating Margin[1]	36.4%	(3.5) ppts
GAAP Diluted EPS	$0.23	(81%)
Non-GAAP Diluted EPS[1]	$1.20	(17%)
Interest Income	$10	(44%)
Interest Expense	$63	NM

Non-GAAP R&D and SG&A

- Y/Y increases reflect Amicus operating expenses, continued pipeline investment and commercial execution
- GAAP SG&A includes ~$84M of transaction- and integration-related charges associated with the Amicus acquisition, which are excluded from Non-GAAP results

Non-GAAP Diluted EPS

- Higher operating expenses and acquisition financing costs drove lower Y/Y EPS

Interest Expense and Interest Income

- Based on current rates, interest expense associated with Amicus financing is estimated at approximately $200 million on an annualized basis
- Due to cash and investments used to fund the acquisition, interest income expected to decrease year-over-year, in near-term

[1]Refer to slide 2 for more detail on Non-GAAP financial measures

Updated Full-year 2026 Guidance

(In millions, except per share amounts)	Prior Guidance As of May 4, 2026	Updated Guidance As of August 6, 2026	Midpoint Growth (Y/Y)
Total Revenues	$3,825 to $3,925	$3,875 to $3,925	↑ 21%
Metabolic Conditions	$2,725 to $2,775	Unchanged	↑ 31%
VOXZOGO	$975 to $1,025	$1,000 to $1,050	↑ 11%
Other Revenues[1]	$100 to $125	Unchanged	
Non-GAAP Diluted EPS[2,3,4]	$4.85 to $5.05	$4.90 to $5.10	↑ 59%[5]

Total Revenues, VOXZOGO, and Non-GAAP Diluted EPS guidance raised, reflecting strong first-half 2026 performance and second-half 2026 revenue expectations for both Metabolic Conditions and VOXZOGO

[1]Other Revenues includes KUVAN, ROCTAVIAN, and royalties. [2]Refer to slide 2 for more detail on Non-GAAP financial measures; [3]Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding; [4]Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%; [5]2025 Non-GAAP Diluted EPS included acquired in-process research & development charges related to the acquisition of Inozyme and an inventory write-off related to the company's strategic decision to voluntarily withdraw ROCTAVIAN from the market

Q&A

Appendix

Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information

Reconciliation of GAAP Reported Net Income to Non-GAAP Income[1]

(In millions of U.S. dollars)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
GAAP Reported Net Income	**$ 45**	**$ 241**	**$ 150**	**$ 426**
Adjustments				
Stock-based compensation expense - COS	5	4	9	6
Stock-based compensation expense - R&D	16	14	28	26
Stock-based compensation expense - SG&A[2]	55	30	83	53
Amortization of intangible assets	73	5	78	10
Amortization of acquired inventory step-up[3]	12	—	12	—
Acquisition-related costs[3]	84	—	84	—
Severance costs [4]	3	—	12	—
Loss on investments [5]	—	—	—	3
Income tax effect of adjustments	(57)	(11)	(70)	(22)
Non-GAAP Income	$ 236	$ 282	$ 385	$ 502

Please refer to slide 27 for footnotes to the table

Reconciliation of GAAP and Non-GAAP COS, R&D, and SG&A Expenses(1)

(In millions of U.S. dollars)

	Three Months Ended June 30,						Six Months Ended June 30,					
	2026			2025			2026			2025		
	COS	R&D	SG&A	COS	R&D	SG&A	COS	R&D	SG&A	COS	R&D	SG&A
GAAP expenses	**$ 203**	**$ 207**	**$ 396**	**$ 150**	**$ 161**	**$ 232**	**$ 398**	**$ 386**	**$ 654**	**$ 302**	**$ 320**	**$ 438**
Adjustments												
Stock-based compensation expense(2)	(5)	(16)	(55)	(4)	(14)	(30)	(9)	(28)	(83)	(6)	(26)	(53)
Amortization of acquired inventory step-up(3)	(12)	—	—	—	—	—	(12)	—	—	—	—	—
Acquisition-related costs (3)	—	—	(84)	—	—	—	—	—	(84)	—	—	—
Severance costs (4)	—	—	(3)	—	—	—	—	—	(12)	—	—	—
Non-GAAP expenses	$ 186	$ 191	$ 253	$ 146	$ 147	$ 203	$ 378	$ 358	$ 475	$ 295	$ 294	$ 385

Please refer to slide 27 for footnotes to the table

Reconciliation of GAAP Income from Operations to Non-GAAP Income from Operations[1]

(In millions of U.S. dollars)

	Three Months Ended June 30,				Six Months Ended June 30,			
	2026	Percent of GAAP Total Revenue	2025	Percent of GAAP Total Revenue	2026	Percent of GAAP Total	2025	Percent of GAAP Total
GAAP Income from Operations	**$ 111**	**11.2 %**	**$ 277**	**33.5 %**	**$ 241**	**13.7 %**	**$ 501**	**31.9 %**
Adjustments								
Stock-based compensation expense[2]	76	7.7	48	5.8	120	6.8	85	5.4
Amortization of intangible assets	73	7.4	5	0.6	78	4.4	10	0.6
Amortization of acquired inventory step-up[3]	12	1.2	—	—	12	0.7	—	—
Acquisition-related costs [3]	84	8.5	—	—	84	4.8	—	—
Severance costs [4]	3	0.3	—	—	12	0.7	—	—
Non-GAAP Income from Operations	$ 360	36.4 %	$ 329	39.9 %	$ 545	31.0 %	$ 596	37.9 %

Please refer to slide 27 for footnotes to the table

Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS[1]

(In U.S. dollars)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
GAAP Diluted EPS	**$ 0.23**	**$ 1.23**	**$ 0.77**	**$ 2.19**
Adjustments				
Stock-based compensation expense[2]	$ 0.38	$ 0.24	0.60	0.43
Amortization of intangible assets	$ 0.37	$ 0.03	0.39	0.05
Amortization of acquired inventory step-up[3]	$ 0.06	$ —	0.06	—
Acquisition-related costs[3]	$ 0.42	$ —	0.42	—
Severance costs [4]	$ 0.02	$ —	0.06	—
Loss on investments [5]	$ —	$ —	—	0.02
Income tax effect of adjustments	$ (0.29)	$ (0.06)	(0.35)	(0.11)
Non-GAAP Diluted EPS	$ 1.20	$ 1.44	$ 1.96	$ 2.57

Please refer to slide 27 for footnotes to the table

Reconciliation of GAAP Weighted-Average Diluted Shares Outstanding to Non-GAAP Weighted-Average Diluted Shares Outstanding(1)

(In U.S. dollars)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
GAAP Weighted-Average Diluted Shares Outstanding	**194.5**	**197.1**	**194.1**	**196.6**
Adjustments				
Common stock issuable under company's convertible debt (6)	4.4	—	4.4	—
Non-GAAP Weighted-Average Diluted Shares Outstanding	198.9	197.1	198.5	196.6

(1) Certain amounts may not sum or recalculate due to rounding.
(2) Stock-based compensation expense recorded in SG&A for the three and six months ended June 30, 2026, includes approximately $13 million related to the post-combination service period for unvested Amicus stock options.
(3) These amounts represent costs resulting from the Amicus acquisition that closed on April 27, 2026. Acquisition-related costs were included in SG&A and consisted of severance, transaction and integration costs. Amortization of acquired inventory -up was included in COS.
(4) These amounts were included in SG&A and represent charges for severance in connection with the company's plan to simplify its organizational design and strategic initiatives in the first and second quarters of 2026.
(5) Represents impairment loss on non-marketable equity securities recorded in Other income, net, in the first quarter of 2025.
(6) Common stock issuable under the company's convertible debt were excluded from the computation of GAAP Weighted-Average Diluted Shares Outstanding for the three and six months ended June 30, 2026 as they were anti-dilutive.

Amicus Therapeutics, Inc.(1)
Reconciliation of Non-GAAP Financial Measures
(In thousands of U.S. dollars)

	Twelve Months Ended December 31, 2025
Total operating expenses - as reported GAAP	**$ 528,492**
Research and development:	
Share-based compensation	12,156
Selling, general and administrative:	
Share-based compensation	75,254
Loss on impairment of assets	1,702
Depreciation and amortization	7,460
Total operating expense adjustments to reported GAAP	96,572
Total operating expenses - as adjusted	$ 431,920

(1) The above historical reconciliation is reproduced from Amicus' earnings release furnished as Exhibit 99.1 to its Current Report on Form 8-K dated February 20, 2026 and reflects Amicus' historical definitions of the applicable non-GAAP measures.